8-K 1 purduesalesforce05132013.htm FORM 8-K PurdueSalesForce 05.13.2013


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________ 
FORM 8-K
_______________________  
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

May 13, 2013 (May 13, 2013)
Date of Report (date of earliest event reported)
_______________________  
TRANSCEPT PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
 
 
 
 
 
 
Delaware
 
000-51967
 
33-0960223
(State or other jurisdiction
of incorporation or organization)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification Number)
1003 W. Cutting Blvd., Suite #110
Point Richmond, California 94804
(Address of principal executive offices)
(510) 215-3500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_______________________  
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))








Item 8.01.    Other events.
On May 13, 2013, Transcept Pharmaceuticals, Inc. (“Transcept”) was notified by Purdue Pharmaceutical Products L.P. (“Purdue”), the Transcept U.S. commercialization partner for Intermezzo® (zolpidem tartrate) sublingual tablet C-IV, that Purdue would no longer be utilizing the 90 contract sales representatives dedicated exclusively to promoting Intermezzo. Commercialization of Intermezzo will continue to be supported by Purdue’s established analgesic sales force, consisting of approximately 525 sales representatives, and other select promotional activities.


 



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
TRANSCEPT PHARMACEUTICALS, INC.
 
 
 
 
Date: May 13, 2013
 
 
 
By:
 
/s/ Leone D. Patterson
 
 
 
 
 
 
Name:   Leone D. Patterson
 
 
 
 
 
 
Title:     Vice President, CFO